While these technologies are now a therapeutic reality, the ASGCT 2024 annual meeting this week was a reminder of just how ...

Novavax Soars on $1.4B Deal With Sanofi for COVID Vaccine - read this article along with other careers information, tips and ...

With its $525 million investment, Royalty Pharma will acquire the royalties and milestones for ImmuNext’s anti-CD40 therapy ...

Anticipating approval for its COPD therapy ensifentrine, Verona has entered into a $650 million financing deal with Oaktree ...

MacroGenics’ stock dropped by as much as 70% Friday morning after the biotech disclosed five deaths in the Phase II TAMARACK ...

Bluebird bio released its first-quarter 2024 business report on Thursday, touting a nearly 140% year-over-year increase in revenue amid the growing uptake of its three gene therapies. The ...

Overview: In this Q&A, Cell Process Development Scientist at AGC Biologics Cell and Gene Center of Excellence Sara Morlacchi, provides her expert analysis on the current state of the cell therapy ...

The American Society of Gene & Cell Therapy’s 27th annual meeting kicks off Tuesday in Baltimore, with a record 2,000 abstracts to be presented. ASGCT President Jeffrey Chamberlain told BioSpace this ...

ASGCT 2024 session, CBER Director Peter Marks made the case for a better, “more convergent” global framework on cell and gene ...

The Bay Area–based biotech plans to use the funds to advance two lead programs, one to treat atopic dermatitis and another ...

As competition with Eli Lilly heats up, Novo Nordisk has partnered with Flaghip’s Metaphore Biotechnologies to take ...

After a combination with Eisai’s Lenvima failed to improve survival in advanced disease in December, adjuvant Keytruda plus chemotherapy missed the mark in newly diagnosed, high-risk patients.